non-U.S. trial

Drisapersen-treated trial participants with Duchenne MD had higher levels of dystrophin protein in their muscle samples at 25 weeks than did placebo-treated participants

posted on August 21, 2013 - 12:17pm
Multinational pharmaceutical company GlaxoSmithKline (GSK) has released encouraging results about dystrophin protein production in a phase 2, non-U.S. trial of its exon-skipping compound drisapersen in boys with Duchenne muscular dystrophy (DMD).

New content is being added every day. Please check back again.